Ann: EGM Notice of Meeting to Approve Dual Listing to Nasdaq, page-8

For mxc it created serious value DL on London stock exchange. It is valued at 50million dollars right now with no prospects. Only at Pre clinical stage. So far off phase 3 its not funny and with 4million cash in bank end of march... would be close to 1 million cash in bank now...
So medlab being funded to complete phase 3 nanabis cashed up dual listed nasdaq with mrna nanocelle. Cpuld bring some serious value. One would imagine multiple of mxc value? With serious cash in bank post DL. With tilray and aphria merging.. medlab nanocelle nanabis alone being double more bioavailable than any other cannabis drug on the market and 5x more bioavailable tin other drugs could get bought out pretty quickly or some serious value added to the company. May be rock bottom as it is valued at 15 million aus$